


### **Summary**

- Scope of Pillar 3 reporting and key challenges
- How useful is the SFCR?
- Approaches taken by insurers
- Where to next for regulatory reporting?

12 October 2017


### Scope of Pillar 3 reporting and key challenges




### **Reducing reporting timeframes**



# Post submission challenges



### **SFCR** components



#### How useful is the SFCR?

"SFCR incremental value add, but limited insight on its own ... more a compendium to the financial statements/notes (in the annual report) and/or a supplementary to the analyst presentations.

Source: Goldman Sach:

"The Solvency II solvency and financial condition report (SFCR) is causing consternation among insurers. How do participants balance the requirements of disclosure with confidentiality, or interpret this most loose fitting of regulatory diktats? With the first set of reports already published, the answer seems to be, not very happily."

Source: InsuranceERI

"It's not intended to be a detailed technical report but should be understood by policyholders and key interested parties,"

Kevin Borrett - Advantage Insurance Company

Source: InsuranceERM

"Solvency II has helped provide a clearer picture of capital adequacy for European insurers, providing some guidance as to when dividends may be a risk or additional capital may be returned. However, Solvency II disclosures have not always considered the investor perspective, creating issues for external users in understanding performance and the dividend paying capacity."

Andrew Crean, Autonomous Research

### **SFCR: Market comments**

#### **Overall**

Limited market reaction

#### Good

Better view of capital adequacy
More granular view of subsidiary capital
ratios, gearing levels and quality of
capital

#### Bad


Not helpful for understanding performance, cash generation Unclear around dividend paying capacity Other disclosures provide incremental value add

#### **Ugly**

Long-term guarantee measures distort ratios

Investors see TMTP capital as lower quality


### **TMTP** and **MA** impacts on coverage ratios



\* Note: Rothesay Life capped the impact of removing TMTP and MA such that eligible own funds do no go negative in S.22.01


Solvency II coverage ratio Solvency II coverage ratio without TMTP Solvency II coverage ratio without TMTP and MA

### **Technical Provisions by product**




Technical Provisions (£bn)	Aviva Group	Just Group	L&G Group	LV= Group	Prudentia I Group	Phoenix Group	PIC Group	Re Assure Group	Rothesay Life		Scottish Equitable	Scottish widows Group	Standard Life Group
Life (excluding UL and IL)	183.5	15.8	60.5	9.0	173.3	38.5	19.8	21.5	19.5	35.7	16.4	32.1	44.5
Life (IL and UL)	148.3	0.03	322.1	2.5	37.1	30.5	0.0	21.5	0.0	32.2	45.9	75.9	100.8
Non-Life	12.4	0.0	0.1	2.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0
Total TP's Source: S 02 01 ORT from SECRs	344.2	15.8	382.8	13.4	210.5	69.0	19.8	43.1	19.5	67.9	62.2	108.3	145.3

## SCR by risk module



### **Own funds tiering**

Quality of Solvency II capital



Source: S.23.01 QRTs from SFCRs

#### SFCR: KPMG observations

· Based on sample of SFCRs across life and non-life.



#### **Business and Performance**

- Majority do not have Brexit as a significant event
- Good level of disclosures about business without reference to other documents



#### Valuation

- Lack of quantitative explanation of differences between IFRS and SII
- Some confusion and lack of clarity around alternative valuation methods.
- Maximize the use of quoted market prices to determine fair value of assets and liabilities

### **SFCR: KPMG observations**



#### **System of Governance**


- Good narrative disclosures on remuneration
- Few quantitative disclosures with focus on remuneration policies
- Clear distinctions of fixed and variable components




#### **Capital Management**

- Lack of disclosure around subordination and loss absorbency
- Availability of own funds around the group not well considered
- Minimum disclosure on capital management

### SFCR: KPMG observations




### SFCR - How useful is it?



### SFCR - size of solo submissions


Section	A Business Performance	B System of Governance	C Risk profile	D Valuation for Solvency purposes	E Capital management		
Industry average for 30 solo (no of pages)	07	16	10	13	07	Minimum	Maximi
Minimum (no of pages)	02	04	01	04	02	number of pages	number
Maximum (no of pages)	13	36	21	29	19		
	In	dustry avera	ige 54 p	pages		19	92
Source: KPMG an	alysis						

# Disclosures on using cost method




Source: KPMG analysis

# Disclosures on alternative valuation techniques




Source: KPMG analysis

### **Disclosures on capital management**




10

### Disclosures on own funds composition




Source: KPMG analysis

### **Disclosures on group consolidation**



Source: KPMG analysis

### Disclosures on fungibility & transferability



### Where to next for regulatory reporting?

"I plan to conduct a review of our implementation of Solvency II reporting requirements, with a view to identifying ways in which we might reduce insurers' reporting burdens while fully meeting out statutory objectives... We remain open to discussions with the ABI and other stakeholders and will survey a sample of insurers to gather information on the impact of reporting through the firm. We will also review the ongoing usefulness of the data collected in supporting the PRA's supervisory functions, and the extent to which the information collected helps the PRA to meet and balance its objectives."

### Where to next for regulatory reporting?

**David Rule** 

Speech to ABI

6 July 2017

It would be unhelpful for the PRA to be too prescriptive about the depth of SFCRs. But it strikes me that some areas could be made more consistent. For example, changes in Solvency Capital Requirement coverage could be broken down to show what is attributable to changes in capital, to changes in modelling and to changes in risk assumptions. Insurers need to explain fully to policyholders, investors and others what lies behind their Solvency II ratios. This is particularly true in more complex areas like internal models and the matching adjustment. Otherwise we run the risk of a loss of confidence in those numbers in a crisis.

25

# **Questions**

# Comments

The views expressed in this presentation are those of invited contributors and not necessarily those of the IFoA. The IFoA do not endorse any of the views stated, nor any claims or representations made in this [publication/presentation] and accept no responsibility or liability to any person for loss or damage suffered as a consequence of their placing reliance upon any view, claim or representation made in this presentation.

The information and expressions of opinion contained in this publication are not intended to be a comprehensive study, nor to provide actuarial advice or advice of any nature and should not be treated as a substitute for specific advice concerning individual situations. On no account may any part of this presentation be reproduced without the written permission of the IFoA and KPMG ILP

05 October 2017 26

13

### **Contact details**



**Matthew Francis** 

Phone: 0207 311 5506

Email: matthew.francis@kpmg.co.uk

05 October 2017 27